May 4, 2020 / 11:56 AM / a month ago

BRIEF-Vir and Alnylam Identify RNAi Therapeutic Development Candidate for the Treatment of COVID-19

May 4 (Reuters) - Alnylam Pharmaceuticals Inc:

* VIR AND ALNYLAM IDENTIFY RNAI THERAPEUTIC DEVELOPMENT CANDIDATE, VIR-2703 (ALN-COV), TARGETING SARS-COV-2 FOR THE TREATMENT OF COVID-19

* ALNYLAM PHARMACEUTICALS INC - COMPANIES EXPECT TO START HUMAN CLINICAL TRIALS AT OR AROUND YEAR-END 2020

* ALNYLAM PHARMACEUTICALS INC - PLAN TO SOON MEET WITH FDA TO DISCUSS A POTENTIAL ACCELERATED PATH FOR FILING IND AT OR AROUND YEAR-END 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below